Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Grows By 40.0%

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 700 shares, a growth of 40.0% from the March 15th total of 500 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 13,500 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Tema Cardiovascular and Metabolics ETF

An institutional investor recently raised its position in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. grew its stake in shares of Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) by 5.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,703 shares of the company’s stock after acquiring an additional 9,008 shares during the period. Tema Cardiovascular and Metabolics ETF comprises approximately 1.2% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 24th biggest position. Sterling Investment Advisors Ltd. owned 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Tema Cardiovascular and Metabolics ETF Stock Performance

Shares of NASDAQ HRTS opened at $27.69 on Friday. Tema Cardiovascular and Metabolics ETF has a 1 year low of $25.32 and a 1 year high of $36.03. The stock’s 50-day simple moving average is $29.28 and its 200-day simple moving average is $30.63. The firm has a market cap of $53.72 million, a price-to-earnings ratio of 27.70 and a beta of 0.93.

Tema Cardiovascular and Metabolics ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.